NO20032733L - Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse - Google Patents

Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse

Info

Publication number
NO20032733L
NO20032733L NO20032733A NO20032733A NO20032733L NO 20032733 L NO20032733 L NO 20032733L NO 20032733 A NO20032733 A NO 20032733A NO 20032733 A NO20032733 A NO 20032733A NO 20032733 L NO20032733 L NO 20032733L
Authority
NO
Norway
Prior art keywords
diphenyllazetidinone
derivatives
compounds
preparation
drugs containing
Prior art date
Application number
NO20032733A
Other languages
English (en)
Other versions
NO20032733D0 (no
Inventor
Heiner Glombik
Werner Kramer
Stefanie Flohr
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10064402A external-priority patent/DE10064402A1/de
Priority claimed from DE2001154520 external-priority patent/DE10154520A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20032733D0 publication Critical patent/NO20032733D0/no
Publication of NO20032733L publication Critical patent/NO20032733L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20032733A 2000-12-21 2003-06-16 Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse NO20032733L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064402A DE10064402A1 (de) 2000-12-21 2000-12-21 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001154520 DE10154520A1 (de) 2001-11-07 2001-11-07 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2001/014532 WO2002050068A1 (de) 2000-12-21 2001-12-11 Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
NO20032733D0 NO20032733D0 (no) 2003-06-16
NO20032733L true NO20032733L (no) 2003-08-14

Family

ID=26008045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032733A NO20032733L (no) 2000-12-21 2003-06-16 Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse

Country Status (24)

Country Link
US (1) US6498156B2 (no)
EP (1) EP1345932B1 (no)
JP (1) JP2004516293A (no)
KR (1) KR20030061462A (no)
CN (1) CN1222522C (no)
AR (1) AR034282A1 (no)
AT (1) ATE342899T1 (no)
AU (2) AU1917302A (no)
BR (1) BR0116482A (no)
CA (1) CA2431985A1 (no)
CZ (1) CZ20031731A3 (no)
DE (1) DE50111293D1 (no)
EE (1) EE200300237A (no)
HK (1) HK1059936A1 (no)
HR (1) HRP20030499A2 (no)
HU (1) HUP0401067A2 (no)
IL (1) IL156552A0 (no)
MX (1) MXPA03005018A (no)
NO (1) NO20032733L (no)
NZ (1) NZ526592A (no)
PL (1) PL362173A1 (no)
SK (1) SK7812003A3 (no)
WO (1) WO2002050068A1 (no)
YU (1) YU46903A (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
HUP0303915A3 (en) * 2001-01-26 2012-12-28 Merck Sharp & Dohme Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TW200744638A (en) * 2001-01-26 2007-12-16 Schering Corp Combinations of bile acid sequestrant(s) and sterol absorption inhibitors and treatments for vascular indications
AR032403A1 (es) * 2001-01-26 2003-11-05 Schering Corp Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
HUP0401318A3 (en) * 2001-08-22 2008-03-28 Sanofi Aventis Deutschland Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DK1429756T3 (da) * 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP2006501205A (ja) * 2002-07-30 2006-01-12 カリキオン インコーポレイテッド エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP5172146B2 (ja) * 2003-05-09 2013-03-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 癌を標的化するための組成物及び方法
WO2005021495A2 (en) * 2003-08-25 2005-03-10 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
AU2004303742B2 (en) 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
WO2005067903A1 (en) * 2004-01-20 2005-07-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
AU2005299771A1 (en) * 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
JP5254620B2 (ja) 2004-12-03 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｂ１アンタゴニストとしての置換ピペラジン
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
KR20080023296A (ko) * 2005-05-09 2008-03-13 마이크로비아 인코포레이티드 유기금속 벤젠포스포네이트 커플링제
JP2008540557A (ja) * 2005-05-11 2008-11-20 マイクロビア インコーポレーテッド フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2007001975A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007047724A2 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
AU2007207706A1 (en) * 2006-01-18 2007-07-26 Merck Sharp & Dohme Corp. Cannibinoid receptor modulators
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008039829A2 (en) * 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
JP2010531361A (ja) * 2007-06-28 2010-09-24 インターベット インターナショナル ベー． フェー． Ｃｂ１アタゴニストとしての置換ピペラジン
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9606319A (es) * 1994-06-20 1997-05-31 Schering Corp Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
PT781278E (pt) * 1994-09-13 2001-08-30 Monsanto Co Novas benzotiepinas com actividade inibidora do transporte de acido biliar ileal e da remocao do taurocolato
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
NO20032733D0 (no) 2003-06-16
KR20030061462A (ko) 2003-07-18
CZ20031731A3 (cs) 2003-09-17
SK7812003A3 (en) 2004-01-08
JP2004516293A (ja) 2004-06-03
CN1222522C (zh) 2005-10-12
IL156552A0 (en) 2004-01-04
US20020128252A1 (en) 2002-09-12
HRP20030499A2 (en) 2005-04-30
HK1059936A1 (en) 2004-07-23
BR0116482A (pt) 2004-02-03
AU1917302A (en) 2002-07-01
DE50111293D1 (de) 2006-11-30
WO2002050068A1 (de) 2002-06-27
HUP0401067A2 (hu) 2004-09-28
CA2431985A1 (en) 2002-06-27
EE200300237A (et) 2003-08-15
EP1345932B1 (de) 2006-10-18
AR034282A1 (es) 2004-02-18
ATE342899T1 (de) 2006-11-15
NZ526592A (en) 2004-11-26
US6498156B2 (en) 2002-12-24
YU46903A (sh) 2006-05-25
PL362173A1 (en) 2004-10-18
CN1481381A (zh) 2004-03-10
AU2002219173B2 (en) 2006-06-22
MXPA03005018A (es) 2003-09-25
EP1345932A1 (de) 2003-09-24

Similar Documents

Publication Publication Date Title
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20032735L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
NO20006251D0 (no) Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20025879D0 (no) Acylfenylureaderivater, fremgangsmåte for fremstilling derav og deres anvendelse som et legemiddel
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
DK1218341T3 (da) Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
NO20020687L (no) 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20032438L (no) Ortosubstituerte og metasubstituerte bisarylforbindelser, fremgangsmåte forfremstilling derav, deres anvendelse som et medikament samtfarmasöytiske preparater inneholdende forbindelsene
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
NO972881D0 (no) Piperazinderivater, legemidler som inneholder disse, anvendelse derav og fremgangsmåte for deres fremstilling
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
DK1381605T3 (da) Mercaptoacetylamidderivater, en fremgangsmåde til deres fremstilling og deres anvendelse
NO20042906L (no) Deutererte, substituerte pyrazolybenzylsulfonamider og medikamenter som inneholder disse forbindelsene
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20021398D0 (no) 2'-substituerte 1,1'-bifenyl-2-karbonamider, fremgangsmåte for fremstilling, deres anvendelse som medikament såvel somfarmasöytiske preparater inneholdende disse
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20042907L (no) Deutererte, substituerte dihydrofuranoner og medikamenter som inneholder disse forbindelsene
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application